| 1 |
35070271 | Reducing severe cutaneous adverse and type B adverse drug reactions using pre-stored human leukocyte antigen genotypes. | 2022 Jan |
1 |
| 2 |
32439433 | Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗32:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype. | 2021 Jan |
3 |
| 3 |
34039850 | Role of pharmacogenomics in T-cell hypersensitivity drug reactions. | 2021 Aug 1 |
1 |
| 4 |
34175955 | Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01. | 2021 Aug 30 |
7 |
| 5 |
30776417 | HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. | 2019 Jul |
4 |
| 6 |
31158526 | A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms. | 2019 Sep |
3 |